BioCryst shuts internal discovery, closes Birmingham facility; navenibart Phase 3 enrollment complete; guidance improved

BIOCRYST PHARMACEUTICALS INC

Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.
Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line data expected Q3 2027.
Resolved manufacturing delay for ORLADEYO oral pellets; product available early August 2026.
2026 non-GAAP operating expense guidance lowered to $420-440M from $450-470M; revenue guidance reaffirmed at $635-660M.
BCX17725 (Netherton syndrome) Phase 1 Part 4 dosing ongoing; proof-of-concept data expected year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.